Advertisement

Organisation › Details
BioNTech (Group)
BioNTech SE is Europe’s largest privately-held biopharmaceutical company pioneering the development of precision immunotherapies for individualized treatment of cancer and prevention of infectious diseases. The company combines all building blocks for more precise and individualized immunotherapies under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based product candidates through innovative chimeric antigen receptors and T-cell receptor-based compounds to novel checkpoint immunomodulators and small molecules. BioNTech’s product development approach has been validated by seven corporate partnerships with, in chronological order, Genmab, Eli Lilly and Company, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant and Pfizer, and its scientific approach through over 60 peer-reviewed scientific publications. Founded in 2008, BioNTech’s financial shareholders include the Struengmann Family Office as its majority shareholder, Fidelity Management & Research Company, Invus, Janus Henderson Investors, MIG Fonds, Redmile Group, Salvia and several European family offices. *
![]() |
Start | 2008-01-01 established |
Predecessor | University of Mainz (Johannes Gutenberg University) | |
![]() |
Industry | cancer immunotherapy (immuno-oncology, I-O) |
Industry 2 | cancer test | |
![]() |
Person | Sahin, Ugur (BioNTech 201207 Managing Director BioNTech + Ribological GmbH) |
Person 2 | Pötting, Sierk (BioNTech 201409– CFO before Sandoz Inc/Novartis + McKinsey) | |
![]() |
Region | Mainz |
Country | Germany | |
Street | 12 An der Goldgrube | |
City | 55131 Mainz | |
Tel | +49-6131-9084-0 | |
Address record changed: 2020-12-11 | ||
Basic data | Employees | D: 101 to 500 (2014-10-01) |
Currency | EUR | |
Annual sales | 108,589,000 (revenues, consolidated (2019) 2019-12-31) | |
Profit | -179,172,000 (2019-12-31) | |
Cash | 451,597,000 (2020-03-31) | |
* Document for �About Section�: BioNTech SE. (5/8/19). "Press Release: BioNTech Acquires MabVax Therapeutics’ Antibody Assets to Expand Portfolio". Mainz. | ||
Record changed: 2020-12-30 |
Advertisement

More documents for BioNTech (Group)
- [1] Evonik Industries AG. (2/11/21). "Press Release: Evonik Strengthens Strategic Partnership with BioNTech on COVID-19 Vaccine". Essen....
- [2] BioNTech SE. (12/29/20). "Press Release: Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of Comirnaty". New York, NY & Mainz....
- [3] BioNTech SE. (12/23/20). "Press Release: Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine". New York, NY & Mainz....
- [4] BioNTech SE. (12/21/20). "Press Release: Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine". New York, NY & Mainz....
- [5] BioNTech SE. (12/21/20). "Press Release: Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine". New York, NY & Mainz....
- [6] BioNTech SE. (12/19/20). "Press Release: Pfizer and BioNTech Receive Conditional Marketing Authorization by Swissmedic for COVID-19 Vaccine". Zürich & Mainz....
- [7] BioNTech SE. (12/16/20). "Press Release: BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine". Mainz & Shanghai....
- [8] BioNTech SE. (12/12/20). "Press Release: U.S. CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and BioNTech COVID-19 Vaccine for Persons Ages 16 Years and Older". New York, NY & Mainz....
- [9] BioNTech SE. (12/11/20). "Press Release: Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19". New York, NY & Mainz....
- [10] BioNTech SE. (11/25/20). "Press Release: BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies". Mainz & London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top